Efficacy and Safety of Dual-Drug-Eluting Stents for de Novo Coronary Lesions in South Korea-The Effect Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cha, Jung-Joon | - |
dc.contributor.author | Kim, Gi Chang | - |
dc.contributor.author | Hur, Seung Ho | - |
dc.contributor.author | Bae, Jang Ho | - |
dc.contributor.author | Choi, Jae Woong | - |
dc.contributor.author | Jin, Dong-Kyu | - |
dc.contributor.author | Woo, Seong Il | - |
dc.contributor.author | Lee, Seung Uk | - |
dc.contributor.author | Park, Jong Seon | - |
dc.contributor.author | Cho, Yun-Hyeong | - |
dc.contributor.author | Choi, Cheol Ung | - |
dc.contributor.author | Lim, Do-Sun | - |
dc.contributor.author | Ahn, Tae Hoon | - |
dc.date.accessioned | 2021-08-30T04:32:03Z | - |
dc.date.available | 2021-08-30T04:32:03Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/50200 | - |
dc.description.abstract | Background: Drug-eluting stents (DESs) are commonly used in percutaneous coronary intervention (PCI) procedures; however, complications including in-stent restenosis and stent thrombosis are significant challenges. The dual-DES is a stent that elutes two drugs to target various stages of the restenosis reaction. This study investigated the safety and efficacy of dual-DES in clinical practice. Methods: This study included 375 patients who underwent PCI with Cilotax((TM)) or DXR (TM) dual-DESs at one of 13 centers in South Korea. The primary endpoint was target lesion failure (TLF) within 1 year. The secondary endpoints were cardiac death, myocardial infarction (MI), target lesion revascularization (TLR), and stent thrombosis. Results: The rates of TLF in dual-DESs (3.7%) were comparable to those reported in conventional DES. In addition, the DXR (TM) group had a significantly lower rate of TLF than the Cilotax((TM)) group. In multivariate analysis, the DXR (TM) group had a lower risk of TLF (adjusted hazard ratio (HR) 0.30, 95% CI 0.09-0.92, p = 0.036) and MI (adjusted HR 0.16, 95% CI 0.03-0.82, p = 0.027) than the Cilotax((TM)) group. Conclusion: Dual-DESs had similar clinical outcomes regarding efficacy and safety as conventional DES. Among the dual-DES, the DXR (TM) stent as a new generation dual-DES had more favorable clinical outcomes than the Cilotax((TM)) stent. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | ANTIPLATELET THERAPY | - |
dc.subject | DIABETES-MELLITUS | - |
dc.subject | RANDOMIZED-TRIAL | - |
dc.subject | ARTERY-DISEASE | - |
dc.subject | CILOSTAZOL | - |
dc.subject | RESTENOSIS | - |
dc.subject | THROMBOSIS | - |
dc.subject | IMPLANTATION | - |
dc.subject | CILOTAX | - |
dc.subject | TRIPLE | - |
dc.title | Efficacy and Safety of Dual-Drug-Eluting Stents for de Novo Coronary Lesions in South Korea-The Effect Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Cha, Jung-Joon | - |
dc.contributor.affiliatedAuthor | Choi, Cheol Ung | - |
dc.contributor.affiliatedAuthor | Lim, Do-Sun | - |
dc.contributor.affiliatedAuthor | Ahn, Tae Hoon | - |
dc.identifier.doi | 10.3390/jcm10010069 | - |
dc.identifier.scopusid | 2-s2.0-85114067012 | - |
dc.identifier.wosid | 000606157900001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL MEDICINE, v.10, no.1, pp.1 - 9 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL MEDICINE | - |
dc.citation.title | JOURNAL OF CLINICAL MEDICINE | - |
dc.citation.volume | 10 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | ANTIPLATELET THERAPY | - |
dc.subject.keywordPlus | DIABETES-MELLITUS | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | ARTERY-DISEASE | - |
dc.subject.keywordPlus | CILOSTAZOL | - |
dc.subject.keywordPlus | RESTENOSIS | - |
dc.subject.keywordPlus | THROMBOSIS | - |
dc.subject.keywordPlus | IMPLANTATION | - |
dc.subject.keywordPlus | CILOTAX | - |
dc.subject.keywordPlus | TRIPLE | - |
dc.subject.keywordAuthor | dual drug-eluting stent | - |
dc.subject.keywordAuthor | Cilotax (TM) stent | - |
dc.subject.keywordAuthor | DXR (TM) stent | - |
dc.subject.keywordAuthor | coronary artery disease | - |
dc.subject.keywordAuthor | clinical outcome | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.